Icosavax’s self-assembling vaccine platform
With $51M in series A funds, Icosavax aims to show its de novo protein VLPs make potent vaccines for RSV
Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its first program through Phase Ib testing.
Virus-like particles (VLPs) -- viral proteins that self-assemble into inert nanoparticles that resemble viral capsids -- have found clinical and commercial success in vaccines including HPV vaccine Gardasil from Merck